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INTRODUCTION
Oral route is the most desired, convenient and preferred method of administering the drug
for  its  systemic  effect  due  to  its  ease  of  administration,  low  cost  of  therapy  and  patient
compliance. Oral route of administration has received more attention in the pharmaceutical field
because  of  more  flexibility  in  the  designing  of  dosage  form  than  the  other  routes  of  drug
delivery1. The release of drug from the delivery system may be by diffusion, dissolution or by
combination of both mechanisms in a desired and controlled manner. One main prerequisite for
the oral  performance  of  the  drug delivery system is  that  drug  should have  good absorption
throughout the gastrointestinal tract (GIT).
Floating drug delivery systems (FDDS) are aimed to retain the drug in the stomach and are
useful  for drugs that are poorly soluble or unstable in intestinal  fluids. The principle is very
simple i.e., to make the dosage form less dense than the gastric fluids so that it can float on them.
Floating systems or  Hydrodynamically controlled systems are low-density systems that  have
sufficient buoyancy to float over the gastric contents and remain buoyant in the stomach without
affecting the gastric emptying rate for a prolonged period of time. After release of drug, the
residual system is emptied from the stomach. This result an increased gastric residence time and
a  better  control  of  the  fluctuations  in  plasma  drug  concentration.  The  principle  of  buoyant
preparation offers a simple and practical approach to achieve increased gastric residence time for
the dosage form and sustained drug release 1. Under certain circumstances prolonging the gastric
retention of a delivery system is desirable for achieving greater therapeutic benefit of the drug
substance. For example, drugs that are absorbed in the proximal part of the gastrointestinal tract
and drugs that are less soluble in or are degraded by the alkaline pH may benefit from prolonged
gastric retention. In addition, for local and sustained drug delivery to the stomach and proximal
small intestine to treat certain conditions, prolonged gastric retention of the therapeutic moiety
may offer numerous advantages including improved bioavailability and therapeutic efficacy, and
possible reduction of dose size.2
Gastro retentive drug delivery systems are the systems which are retained in the stomach for a
longer period of time and thereby improve the bioavailability of drugs3. 
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Gastric emptying of dosage form is an extremely variable process and ability to prolong and
control emptying time is a valuable asset for dosage forms, which reside in the stomach for a
longer period of time than conventional dosage forms .Several difficulties are faced in designing
controlled  release  systems  for  better  absorption  and  enhanced  bioavailability  .One  of  such
difficulties  is  the inability to  confine the dosage form in  the  desired area of  the GIT .Drug
absorption from the GIT is a complex procedure and is subject to many variables, it is widely
acknowledged that the extent of gastro intestinal tract drug absorption is related to contact time
with the small intestinal mucosa. Thus small intestinal transit time is an important parameter for
drugs that are incompletely aabsorbed4. 
The  oral  controlled  drug  delivery  systems  should  be  primarily  used  to  achieving  more
predictable  and  increased  bioavailability  of  drugs.  Prolonged  gastric  retention  improves
bioavailability, reduces drug waste, useful for drugs acting locally in the GIT, drugs which are
poorly soluble and unstable in the intestinal fluids. Among the various gastro retentive systems,
gastric  floating drug delivery systems (GFDDS) offer  numerous advantages  over  the  gastric
retentive systems. These systems have a density lower than the gastric fluids and thus remain
buoyant in the stomach without affecting the gastric emptying rate for a prolonged period of time
.While the system is floating on the gastric contents, the drug is released slowly at a desired rate
from the stomach. Floating drug delivery and mucoadhesive systems gained significant attention
in the past decade because of its effectiveness in gaining bioavailability, cost-effective compared
to other NDDS and better scale up technical opportunities.
Issues related to gastric emptying: 
It  is well recognized that the stomach may be used as a ‘depot ‘for sustained release dosage
forms, both in human and veterinary applications. Anatomically the stomach is divided into 3
regions: fundus, body and anthrum (pylorus). The proximal part made of fundus and body acts as
a reservoir for undigested material, where as the anthrum is the main site for mixing motions and
act as a pump for gastric emptying by propelling actions5. 
Gastric emptying occurs during fasting as well as fed states. The pattern of motility is however
distinct in the 2 states. During the fating state an inter digestive series of electrical events take
place, which cycle both through stomach and intestine every 2 to 3 hours6. 
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This is called as the inter digestive myloelectric cycle or migrating myloelectric cycle (MMC),
which is further divided into following 4 phases as described by Wilson and Washington6. 
1. Phase I (basal phase) lasts from 40 to 60 minutes with rare contractions. 
2. Phase II (pre burst phase) lasts for 40 to 60 minutes with intermittent action potential and
contractions. As the phase progresses the intensity and frequency also increases gradually.
3. Phase III (burst phase) lasts for 4 to 6 minutes .It includes intense and regular contractions for
short period. It is due to this wave that all the undigested material is swept out of the stomach
down to the small intestine .it is also known as house keeper wave. Phase IV lasts for 0 to 5
minutes and occurs between phases III and I of 2 consecutive cycles. After the ingestion of a
mixed meal, the pattern of concentrations changes from fasted to that of fed state.
This is also known as digestive motility pattern and comprises continuous contractions as in
phase II of fasted state. These contractions result in reducing the size of food particles (to less
than 1mm), which are propelled towards the pylorus in a suspension form. During the fed state
onset of MMC is delayed resulting in showdown of gastric emptying rate. 
Scintigraphic  studies  determining  gastric  emptying  rates  revealed  that  orally  administered
controlled release dosage forms are subjected to basically 2 complications, that of short gastric
emptying residence time and unpredictable gastric emptying rate. Yet another major adversity
encountered  through  the  oral  route  is  the  first-pass  effect,  which  leads  to  reduced  systemic
bioavailability of a large number of drugs. Overall, the relatively brief GI transit time of most
drug products,  which is  approximately 8-12 hours,  impedes the formulation of  a  once daily
dosage form for most drugs such as age, race, sex and disease states, as they may seriously affect
the release of a drug from the DDS. It is, therefore desirable to have a CR product that exhibits
an extended GI residence and a drug release profile independent of patient related variables7.
Table 1: Regional specific characteristics of GIT influencing gastro retention
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Need for gastro retentive drug delivery system 
Various drugs have their greatest therapeutic effect when released in the stomach, particularly
when the release is prolonged in a continuous, controlled manner. Drugs delivered in this manner
have  a  lower  level  of  side  effect  and  provide  their  therapeutic  effects  without  the  need  for
repeated dosages or with a low dosage frequency. Sustained release in the stomach is also useful
for therapeutic agents that the stomach does not readily absorb, since sustained release prolongs
the contact time of the agent in the stomach or in the upper part of the small intestine, which is
where absorption occurs and contact time is limited. Under normal or average conditions, for
example material  passes  through the small  intestine  in  as  1-3 hours.  In  general,  appropriate
candidates for CRGRDF are molecules that have poor colonic absorption but are characterized
by better absorption properties at the upper parts of the GIT7: 
I. Drugs acting locally in the stomach 
E.g. Antacids and drugs for H.Pylori viz., Misoprostol 
II. Drugs that are primarily absorbed in the stomach 
E.g. Amoxicillin 
III. Drugs that is poorly soluble at alkaline PH 
E.g. Frusemide, Diazepam, Verapamil, etc.
IV. Drugs with a narrow window of absorption 
E.g. Cyclosporine, Methotrexate, Levodopa, etc 
V. Drugs which are absorbed rapidly from the GIT. 
E.g. Metronidazole, tetracycline. 
VI. Drugs that degrade in the colon. 
E.g. Ranitidine, Metformin HCL. 
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VII. Drugs that disturb normal colonic microbes 
E.g. Antibiotics against H.Pylori.
Drugs that would benefit from GRDDS 
CNS drugs (for Parkinson disease, epilepsy, Alzheimer and migraine), Anti-viral products (for
HIV, herpes and hepatitis) and certain antibiotics, Anti-hypertension drugs, Anti-diabetic agents
for Type-2 diabetes, Drugs for local treatment of GI infections and gastric enzyme replacement8.
Formulation considerations for GRDDS 
It must be effective retention in the stomach to suit for the clinical demand 
I) it must have sufficient drug loading capacity 
II) It must be control the drug release profile 
III) It must have full degradation and evacuation of the system once the drug release is over 
IV) It should not have effect on gastric motility including emptying pattern 
V) It should not have other local adverse effects9.
Approaches to gastric retention 
Various attempts have been made to retain the dosage form in the stomach as a way of increasing
the  retention  time.  These  attempts  include  introducing  floating  dosage  forms,  swelling  and
expanding  systems,  Mucoadhesive  systems,  High  density  systems,  Modified  shape  systems.
Gastric  emptying  delaying  devices  and  co-administration  of  gastric  delaying  drugs.  Among
these, the floating dosage forms have been used most commonly. 
A. Floating drug delivery system: 
Floating drug delivery systems (or) hydro-dynamically balanced systems have a bulk density
lower than gastric fluid and thus remain buoyant in the stomach without affecting the gastric
emptying  rate  for  a  prolonged  period  of  time.  While  the  system is  floating  on  the  gastric
contents, the drug is slowly released at a desired rate from the stomach. After the release of drug,
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the residual system is emptied from the stomach. This results an increase in the gastric retention
time and better control of fluctuations in the plasma drug concentration.
The floating sustained release dosage forms present most of the characteristics of hydrophilic
matrices and are known as hydro dynamically balanced systems(HBS) since they are able to
maintain their low apparent density, while the polymer hydrates and builds a gelled barrier at the
outer surface.  The drug is  released progressively from the swollen matrix,  as in the case of
conventional hydrophilic matrices. 
These forms are expected to remain buoyant (3-4 hours) on the gastric contents without affecting
the intrinsic rate of emptying because their bulk density is lower than that of gastric contents. 
Among the different hydrocolloids recommended for floating form formulations, cellulose and
ether polymer are most popular, especially hydroxy propyl methyl cellulose. Fatty material with
a bulk density lower than one may be added to the formulation to decrease the water intake rate
and increase bouncy10, 11. 
Parallel to formulation studies, investigations have been undertaken in animals and humans to
evaluate  the  intra  gastric  retention  performances  of  floating  forms.  These  assessments  were
realized  either  indirectly  through  pharmacokinetic  studies  with  a  drug  tracer,  or  directly  by
means of x-ray and gamma scintigraphic monitoring of the form transit in the gastrointestinal
tract. when a floating capsule is administered to the subjects with a fat and protein meal, it can be
observed that it remains buoyant at the surface of the gastric content in the upper part of the
stomach and moves down progressively while the meals empties. The reported gastric retention
times range from 4 to 10 hours. 
Pharmacokinetic and bioavailability evaluation studies confirm the favorable incidence of this
prolonged gastric residence time12. 
The floating drug delivery system (FDDS) can be divided into effervescent systems and non
effervescent systems. 
I. Effervescent systems: 
A drug delivery system can be made to float in the stomach by incorporating a floating chamber,
which may be filled with vacuum, air or inert gas13. 
These are matrix type systems prepared with the help of swellable polymers such as HPMC,
methylcellulose, chitosan and various effervescent compounds, e.g. sodium bicarbonate, calcium
carbonate, tartaric acid and citric acid. They are formulated in such away that when in contact
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with the gastric contents,  Co2 is liberated and gets entrapped in swollen hydrocolloids, which
provides buoyancy to the dosage forms14. 
i) Volatile liquid / vacuum Containing Systems:- 
These have an inflatable chamber which contains a liquid e.g. ether, cyclopentane, that gasifies
body temperature to cause the inflation chamber in the stomach. These systems are osmotically
controlled floating systems containing a hollow deformable unit.  There are two chambers  in
system first contains the drug and the second chamber contains the volatile liquid .These systems
are classified into 3 categories 
1. Intra gastric floating drug delivery system 
2. Inflatable gastrointestinal delivery systems 
3. Intra-gastric osmotically controlled drug delivery system
a) Intra gastric floating gastrointestinal drug delivery system:- 
These systems can be made to float in the stomach because of floatation chamber, which may be
a vacuum (or) filled with air (or) a harmless gas, while drug reservoir is encapsulated inside a
microporous compartment. 
b) Inflatable gastrointestinal delivery systems 
In these systems an inflatable chamber is incorporated, which contains liquid ether that gasifies
at body temperature to cause the chamber to inflate in the stomach. These systems are fabricated
by loading the  inflatable  chamber  with  a  drug  reservoir,  which  can  be  a  drug,  impregnated
polymeric matrix, then encapsulated in a gelatin capsule. After oral administration, the capsule
dissolves  to  release  the  drug  reservoir  together  with  the  inflatable  chamber.  The  inflatable
chamber automatically inflates and retains the drug reservoir compartment in the stomach. The
drug continuously released from the reservoir into the gastric fluid. 
c) Intragastric osmotically controlled drug delivery system:- 
It is comprised of an osmotic pressure controlled drug delivery device and an inflatable floating
support in a biodegradable capsule. In the stomach, the capsule quickly disintegrates to release
the intragastirc osmotically controlled drug delivery device. The inflatable support inside forms a
deformable hollow polymeric bag that  contains a  liquid that  gasifies  at  body temperature to
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inflate  the  bag.  The  osmotic  pressure  controlled  drug  delivery  device  consists  of  two
components; drug reservoir compartment and an osmotically active compartment. 
The drug reservoir compartment is enclosed by a pressure responsive collapsible bag, which is
impermeable  to  vapor  and  liquid  and  has  a  drug  delivery  orifice.  The  osmotically  active
compartment  contains  an  osmotically  active  salt  and  is  enclosed  within  a  semi-permeable
housing. 
In the stomach, the water in the GI fluid is continuously absorbed through the semi-permeable
membrane  into  osmotically  active  compartment  to  dissolve  the  osmotically  active  salt.  An
osmotic pressure is thus created which acts on the collapsible bag and in turn forces the drug
reservoir  compartment  to  reduce  its  volume and activate  the  drug  reservoir  compartment  to
reduce  its  volume and  activate  the  drug  release  of  a  drug solution  formulation  through the
delivery orifice. 
The floating support is also made to contain a bio-erodible plug that erodes after a predetermined
time to deflate the support. The deflated drug delivery system is then emptied from the stomach. 
ii) Gas generating systems: 
These  buoyant  delivery systems  utilizes  effervescent  reaction  between  carbonate/bicarbonate
salts and citric/tartaric acid to liberate Co2, which gets entrapped in the jellified hydrocolloid
layer  of  the  system,  thus  decreasing  its  specific  gravity  and  making  it  float  over  chime.  A
multiple unit type of floating pills, which generate co2, have also been developed.
The system consists of a sustained release pill as seed, surrounded by double layers. The inner
layer is an effervescent layer containing sodium bicarbonate and tartaric acid. The outer layer is
of  a  swellable  membrane  layer  containing  PVA,  shellac  etc.  Another  effervescent  system
consisting of a collapsible spring, which controls the release of drug from the polymer matrix,
has also been developed. 
The common approach for preparing these systems involves resin beads loaded with bicarbonate
and coated with ethyl cellulose. The coating which is insoluble but permeable, allows permeation
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of water. Thus carbon dioxide is released, causing the beads to float in the stomach15. Earlier we
have reported fabrication of gas liberating Lanzoprazole microsphere16. 
iii) Matrix tablets 
Single  layer  matrix  tablet  is  prepared  by  incorporating  bicarbonates  in  matrix  forming
hydrocolloid gelling agent like HPMC, chitosan, alginate or other polymers and drug. 
Bilayer tabet can also be prepared by gas generating matrix in one layer and second layer with
drug for its sustained release effect. 
Floating capsule also prepared by incorporating such mixtures. Triple layer tablet also prepared
having first swellable floating layer, second sustained release layer of two drugs (metronidazole
and tetracycline) and third rapid dissolving layer of bismuth salt. This tablet is prepared as single
dosage form for triple therapy of H.Pylori14. 
II. Non effervescent system: 
Non  effervescent  floating  dosage  forms  use  a  gel  forming  or  swellable  cellulose  type  of
hydrocolloids, polysaccharides, and matrix-forming polymers like polycarbonate, polyacrylate,
poly methacrylate,  and  polystyrene.  The  formulation  methods  include  a  simple  approach  of
thoroughly mixing  the  drug  and  the  gel  forming  hydrocolloid.  After  oral  administration  the
dosage form swells in contact with gastric fluids and attains a bulk density of less than one. The
air entrapped within the swollen matrix imparts buoyancy to the dosage form. These formed
swollen gel-like structure acts as a reservoir and allows sustained release of drug through the
gelatinous  mass  17,  18.  Corresponding  author  have  utilized compressed  carbon  dioxide  in  the
system slurry to produce microspheres with air pockets by which it becomes buoyant19. 
i) Hydro dynamically balanced systems: 
Hydro dynamically balanced (HBS), which contains drugs with gel forming hydrocolloids meant
to remain buoyant on the stomach content. These are single unit dosage form, containing one or
more  gel-forming  hydrophilic  polymers.  Hydroxy propyl  methyl  cellulose(HPMC),  hydroxyl
ethyl  cellulose  (HEC),  hydroxyl  propyl  cellulose  (HPC),  sodium  carboxymethylcellulose
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(NaCMC),  polycarbophil,  polystyrene,  polyacrylate,  agar  carrageenans  or  alginic  acid  are
commonly used excipients  to  develop these systems.  The  polymer  is  mixed with  drugs  and
usually administered in hydro dynamically balanced system capsule.
The capsule shell dissolves in contact with gastric fluids; the hydrocolloids in the system hydrate
and form a colloidal gel barrier around its surface. This gel  barrier controls the rate of fluid
penetration into the device and consequent release of the drug 4, 17, 18. 
ii) Micro porous compartment systems: 
This  technology  is  based  on  the  encapsulation  of  a  drug  reservoir  inside  a  micro  porous
compartment with apertures along its top and bottom walls. The peripheral walls of the drug
reservoir compartment are completely sealed to prevent any direct contact of the gastric mucosal
surface with the undissolved drug. Gastric fluid enters through the aperture, dissolves the drug
for continuous transport across the intestine for drug absorption.19 
iii) Multi particulate system: Floating beads 
Multi particulate drug delivery systems are mainly oral dosage forms consisting of a multiplicity
of small discrete units, each exhibiting some desired characteristics. In these systems, the dosage
of the drug substances is divided on a plurality of subunit, typically consisting of thousands of
spherical  particles  with  diameter  of  0.05-2.00mm.  Thus  multi  particulate  dosage  forms  are
pharmaceutical  formulations  in  which  the  active  substance  is  present  as  a  number  of  small
independent subunits. To deliver the recommended total dose, these subunits are filled into a
sachet19. 
iv) Micro balloons / hollow microspheres: 
There are various approaches in delivering substances to the target site in a controlled release
fashion.  One such  approach is  using polymeric  micro  balloons as  carrier  for  drugs.  Hollow
microspheres are known as the micro balloons. 
Hollow microspheres loaded with drugs in their other polymer shelf were prepared by simple
solvent evaporation or solvent diffusion evaporation methods to prolong the gastric retention
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time of the dosage form20.Commonly used polymers to develop these systems are polycarbonate,
cellulose acetate, calcium alginate, Eudragit S, agar and low methoxylated pectin etc. Buoyancy
and drug release from dosage form are dependent on quantity of polymers, the plasticizer and
polymer ratio and the solvent used for formulation. The micro balloons floated continuously over
the surface of acidic dissolution media contain surfactant for more than 12 hours21. At present
hollow microspheres are considered to be one of the promising buoyant systems because they
combine the advantages of multiple-unit system and good floating. 
B. Mucoadhesive systems: 
Mucoadhesive systems are those which bind to the gastric epithelial cell surface or mucin and
serve as a potential means of extending the gastro retention of drug delivery system (DDS) in the
stomach  by  increasing  the  intimacy  and  duration  of  contact  of  drug  with  the  biological
membrane.
A bio/muco-adhesive  substance  is  a  natural  or  synthetic  polymer  capable  of  producing  an
adhesive  interaction  based  on  hydration  –mediated,  bonding  mediated  or  receptor  mediated
adhesion with a biological membrane or mucus lining of GI mucosal surface 22, 23. 
C. Swellable systems: 
Swellable systems are also retained because of their mechanical properties. The swelling usually
results from osmotic absorption of water. On coming in contact with gastric fluid, the polymer
imbibes water and swells. These are the dosage forms, which after swallowing, swells to an
extent that prevents their exit from the pylorus. As a result, the dosage form is retained in the
stomach  for  a  longer  period  of  time.  These  systems  may be  named  as  plug  type  systems.
Sustained  and  controlled  drug  release  may be  achieved  by  selection  of  polymer  of  proper
molecular weight and swelling of the polymer retards the drug release. 
D. Expandable system: 
After being swallowed, these dosage forms swell to a size that prevents their passage through the
pylorus24. As a result, the dosage form is retained in the stomach for a longer period of time.
These systems are sometimes referred to  as  plug type systems because they tend  to  remain
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lodged at the pyloric sphincter. As dosage form coming in contact with gastric fluid, the polymer
imbibes water and swells. The extensive swelling of this polymer is a result of the presence of
physical-chemical crosslink’s in the hydrophilic polymer network. These crosslink’s prevented
the dissolution of the polymer and thus maintain the physical integrity of the dosage form. A
balance between the extent and duration of swelling is maintained by the degree of cross linking
between the polymeric chains. A high degree of cross-linking retards the swelling ability of the
system and maintains its physical integrity for a prolonged period .On the other hand, a low
degree of cross-linking results  in extensive swelling followed by the rapid dissolution of the
polymer25.  An  optimum amount  of  cross  linking  is  required  to  maintain  a  balance  between
swelling and dissolution .The swollen system eventually will lose its integrity because of a loss
of mechanical strength caused by abrasion or erosion or will burst into small fragments when the
membrane ruptures because of continuous expansion26.  These systems also may erode in the
presence of gastric juices so that after a predetermined time the device no longer can attain or
retain the expanded configuration 
The expandable GRDFs are usually based on three configurations 27: 
I) A small collapsed configuration which enables sufficient oral intake 
II) Expanded form that is achieved in the stomach and thus prevents passage through the pyloric
sphincter. 
III) A smaller form that is achieved in the stomach when the retention is no longer required i.e.
after the GRDF has released its active ingredient, thereby enabling evacuation. 
The expansion can be achieved by 
I) swelling system 
II) Unfolding system
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E. Self-unfolding systems/Modified shaped system: 
These are non-disintegrating geometric shapes molded from silastic elastomer or extruded from
polyethylene blends which extend the GRT depending on size, shape and flexural modulus of the
drug delivery system28. 
The self unfoldable systems are capable of mechanically increasing in size relative to the initial
dimensions. This increase prevents the system from passing via the pylorus and provides for its
prolonged stay in the stomach .A drug can be either contained in a polymeric composition of the
gastro retentive system or includes as a separate compartment. Several methods were suggested
to provide for the self –unfolding effect29. 
1) The use of hydro gels swelling in contact with the gastric juice. 
2) Osmotic systems, comprising an osmotic medium in a semi permeable membrane. 
3) System based on low boiling liquids converting into a gas at the body temperature. 
F. Magnetic systems: 
This system is based on a simple idea that the dosage form contains a small internal magnet and
magnet placed on the abdomen over the position of the stomach. Despite numerous reports bout
successful tests, the real applicability of such systems is doubtful because the desired results can
be  achieved  only  provided  that  the  magnet  position  is  selected  with  very  high  precision.
Probably, the development of new conveniently applied magnetic field sources will improve this
concept 30, 31. 
G. High density systems: 
These systems with a density of about 3g/cm3 are retained in the anthrum part of the stomach
and are capable of withstanding its peristaltic movements. The only major draw backs with such
system is that it is technically difficult to manufacture such formulations with high amount of
drug (>50%) and to achieve a density of about 2.8g/cm3. It is necessary to use diluents like
barium sulfate, zinc oxide, titanium dioxide, iron powder etc to manufacture such high density
formulations 32, 33. 
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H. Raft forming systems: 
Raft forming systems have received much attention for the delivery of antacids and drug delivery
for  gastrointestinal  infections  and  disorders.  The  mechanism involved  in  the  raft  formation
includes  the formation of  viscous cohesive gel  in contact  with  gastric  fluids,  where in each
portion of the liquid swells forming a continuous layer called a raft. These systems contains a gel
forming agent and alkaline bi carbonate or carbonates responsible for the formation of CO2 to
make the system less dense and float on the gastric fluids6. Formulations also typically contain
antacids such as aluminum hydroxide or calcium carbonate to reduce gastric acidity. Because raft
forming systems produce a layer  on the top of  gastric  fluids,  they are often used for gastro
esophageal reflux treatment as with liquid gaviscon 25, 26, 27.
I. Super porous hydro gels: 
Although these are swellable systems, they differ sufficiently from the conventional  types to
warrant  separate  classification  with  pore  size  ranging  between  10nm  and  10micro  meter
.Absorption of water by conventional hydro gel is very slow process and several hours may be
needed to reach an equilibrium state during which premature evacuation of dosage form may
occur. Super porous hydro gel ,average pore size >100 micro meter, swell to equilibrium size
within a minute,  due to water uptake by capillary wetting through numerous inter connected
open pores. Moreover they swell to a large size (swelling ratio 100 or more) and are intended to
have  sufficient  mechanical  strength  to  withstand  pressure  by  gastric  contractions.  This  is
achieved by a co-formulation of a hydrophilic particulate material, Ac-Di-Sol (croscarmellose
sodium). 
3. Factors affecting the gastro retentive systems: 
Various attempts have been made to retain the dosage form in the stomach as a way of increasing
the retention time. Most of approaches are influenced by a number of factors that affect their
bioavailability and efficacy of the gastro retentive system34. 
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3.1. Dosage related physical factors 
The density of a dosage form also affects the gastric emptying rate and determines the location of
the system in the stomach. Dosage forms having a density lower than the gastric contents can
float to the surface, while high density systems sink to bottom of the stomach .Both positions
may isolate the dosage system from the pylorus. A density of <1.0gm/cm3 is required to exhibit
floating property. 
Size and shape have found to have effect on gastro retention. Dosage form units with a diameter
of more than 7.5mm are reported to have an increased GRT compared with those with a diameter
of 9.9mm. Tetrahedron and ring shaped devices with a flexible modulus of 48 and 22.5 kilo
pounds per square inch (KSI) are reported to have better GRT 90% to 100% retention at 24 hours
compared with other shapes. 
3.2. Single or multiple unit formulation: 
Multiple unit formulations show a more predictable release profile and insignificant impairing of
performance  due  to  failure  of  units,  allow  co-administration  of  units  with  different  release
profiles  or  containing  incompatible  substances  and  permit  a  larger  margin  of  safety  against
dosage form failure compared with single unit dosage forms. For single unit dosage form, either
the whole dosage form retains within the stomach, but if fails no drug will be released in the
gastric region, thus shows ‘all or non hypothesis’.
Table 2: Various reported gastroretentive systems and the APIs and polymers used
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3.3. Fed or unfed state: 
Under fasting conditions, the GI motility is characterized by periods of strong motor activity or
the migrating myoelectric complex (MMC) that occurs every 1.5 to 2 hours. The MMC sweeps
undigested material  from the stomach and, if the timing of administration of the formulation
coincides with that of the MMC, the GRT of the unit can be expected to be very short. However,
in the fed state, MMC is delayed and GRT is considerably longer 25. 
3.4. Nature and frequency of meal: 
Feeding  of  indigestible  polymers  or  fatty  acid  salts  can  change  the  motility  pattern  of  the
stomach to a fed state, thus decreasing the gastric emptying rate and prolonging drug release35.
GRT can be increased by 4 to 10 hours with a high calorie meal (in proteins and fats) 36, 37. The
GRT can increase by over 400 minutes when successive meals are given compared with a single
meal due to the low frequency of MMC. 
3.5. Gender, age, exercise and body posture of subject: 
Mean ambulatory GRT in males  (3.4  +-0.6  hours)  I  less  compared  with  their  age  and  race
matched  female  counterparts  (4.6+_1.2  hours),  regardless  of  the  weight,  height  and  body
surface36.  Elderly  people,  especially  those  over  70  years  of  age,  have  a  significant  longer
GRT25. Vigorous physical activity retards gastric emptying. Gastric emptying is favored while
standing and by lying on the right side since the normal curvature of the stomach provides a
downhill path where as lying on the left side or in supine position retards it since the contents
have to go against gravity 37. 
3.6. Emotional state of subject: 
The influence of emotional factors on gastric motility and secretion may be either augmentative
or  inhibitory  depending  upon  whether  the  emotional  experience  is  of  an  aggressive  or  a
depressive type34. 
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3.7. Gastro intestinal PH: 
Gastric  emptying  is  retarded  at  low  stomach  PH  and  promoted  at  higher  or  alkaline  PH.
Chemicals that effect gastrointestinal PH also alters gastric emptying. The inhibitory effect of
various acids on gastric  emptying decreases  with increase in  molecular  weight and is  in the
following order  HCL>Acetic>lactic>tartaric>citric  acids.  With alkaline solutions,  a  low base
concentration  (1% NaHCO3)  increases  the  gastric  emptying  rate  more  than  the  1  of  higher
concentration (5%). 
3.8. Concomitant drug administration and disease state: 
Anti cholinergics like atropine and propantheline, opiates like codeine and prokinetic agents like
metoclopramide and cisapride can affect floating time. Gastric ulcer, diabetes, hypothyroidism
increase GRT. Hyperthyroidism, duodenal ulcers decrease GRT 7, 24.
Evaluation of Floating Drug Delivery System38, 39: 
I.  Pre-compression parameters like angle of Repose (θ),  Compressibility Index. bulk density,
tapped density, Carr’s index. 
II.  Post-compression  parameters:  Shape  of  Tablets40:  Compressed  tablets  were  examined
under the magnifying lens for the shape of the tablet. 
Tablet Dimensions: Thickness and diameter were measured using a calibrated varniear caliper.
Three  tablets  of  each  formulation  were  picked  randomly  and  thickness  was  measured
individually. 
Determination  of  hardness  of  tablet:  Randomly  sampled  twenty  tablets  in  each  batch  of
formulations should be used for the determination of hardness with the help of Monsanto type
hardness tester. 
Determination  of  weight  variation:  Twenty  tablets  selected  at  the  random  are  weighed
accurately and the average weight of the tablet is calculated. Then the deviation of individual
weight from the average weight is calculated. 
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Determination of thickness of the tablet: The individual crown – to – crown thickness of ten
tablets is determined using slide calipers for each batch. 
Measurement of Floating Capacity: 
Three individual tablets are put in individual flask containing 400ml of 0.1(N) HCL solutions.
Then the time in minutes for each tablets to go from the bottom to the top of the flask (floating
lag  time)  and  the  time for  which  tablets  constantly  float  on  the  water  surface  (duration  of
floating) are measured. The sample mean and standard deviation are then calculated. 
Measurement of the Density of the formulation40:  The apparent densities of the tablets are
calculated from their volumes and masses in triplicate. The volume V of the cylindrical tablets
are calculated from their height h and radius (both determined with a micrometer gauge) using
the mathematical equation for a cylinder 
(V = A × r2 × h).
Determination of drug content in tablets: Three tablets from each batch are selected randomly
and transferred to a 100ml volumetric flask filled up with 0.1(N) HCL. Kept it for 48hours then
took 1ml from each of  volumetric  flask  and  transferred  to  the  test  tubes.  Samples  are  then
filtered, suitably diluted and analyzed spectrophotometrically at a suitable wavelength. 
In-vitro dissolution study: The tablet was placed inside the dissolution vessel. 5ml of sample
were withdrawn at time intervals of 1h, 2h, 3h, 4h, 5h, 6h, 8h, 10 h and 12h. The volume of
dissolution fluid adjusted to 900 ml by replacing fresh 5ml of dissolution medium after each
sampling. The release studies were conducted with 3 tablets, and the mean values were plotted
versus time. Each sample was analyzed at maximum wavelength using double beam UV visible
spectrophotometer against reagent blank and the corresponding concentration was determined
from the respective calibration curve. 
Buoyancy / Floating Test: The time between introduction of dosage form and its buoyancy on
the simulated gastric fluid and the time during which the dosage form remain buoyant were
measured. The time taken for dosage form to emerge on surface of medium called Floating Lag
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Time (FLT) or Buoyancy Lag Time (BLT) and total  duration of time by which dosage form
remain buoyant is called Total Floating Time (TFT)41. 
Swelling Study: The swelling behavior of a dosage form was measured by studying its weight
gain or water uptake. The dimensional changes could be measured in terms of the increase in
tablet  diameter  and/or  thickness  over  time.  Water  uptake  was measured  in  terms of  percent
weight gain, as given by the equation. 
WU = (W1 – W0)/ W0 x 100
Where, Wt = Weight of dosage form at time t. 
W0 = Initial weight of dosage form.
Advantages  of  Floating  Drug  Delivery  System42:  Floating  dosage  systems  are  important
technological drug delivery systems with gastric retentive behavior and offer several advantages
in drug delivery. These advantages Include: 
1. Improved drug absorption, because of increased GRT and more time spent by the dosage form
at its absorption site. 
2. Controlled delivery of drugs. 
3. Delivery of drugs for local action in the stomach. 
4. Minimizing the mucosal irritation due to drugs, by drug releasing slowly at controlled rate. 
5. Acidic substances like aspirin cause irritation on the stomach wall when come in contact with
it. Hence HBS formulation may be useful for the administration of aspirin and other similar
drugs. 
6. Administration of prolongs release floating dosage forms, tablet  or capsules,  will result  in
dissolution  of  the  drug  in  the  gastric  fluid.  They  dissolve  in  the  gastric  fluid  would  be
available for absorption in the small intestine after emptying of the stomach contents. It is
therefore expected that a drug will be fully absorbed from floating dosage forms if it remains
in the solution form even at the alkaline pH of the intestine. 
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7. When there is  a  vigorous intestinal  movement and a short  transit  time as  might  occur in
certain type of diarrhea,  poor absorption is expected. Under such circumstances it  may be
advantageous  to  keep  the  drug in  floating condition in  stomach  to  get  a  relatively better
response. 
8. Treatment of gastrointestinal disorders such as gastro esophageal reflux. 
9. Simple and conventional equipment for manufacture.
10. Ease of administration and better patient compliance. 
11. Site-specific drug delivery. 
Disadvantages of Floating Drug Delivery System 42
The major disadvantage of floating system is requirement of a sufficient high level of fluids in
the stomach for the drug delivery to float. However this limitation can be overcome by coating
the dosage form with the help of bioadhesive polymers that easily adhere to the mucosal lining of
the stomach . 
I. These systems require a high level of fluid in the stomach for drug delivery to float and
work efficiently. 
II. The  drugs  that  are  significantly  absorbed  through  out  gastrointestinal  tract,  which
undergo significant first pass metabolism, are only desirable candidate. 
III. Some drugs present in the floating system causes irritation to gastric mucosa. 
IV. Gastric emptying of floating forms in supine subjects may occur at random and becomes
highly dependent on the diameter and size. Therefore patients should not be dosed with
floating forms just before going to bed. 
Criteria Selection of Drug Candidate for FDDS42 
1. Absorption from upper GIT e.g. Ciprofloxacin. 
2. Drugs having low pKa, which remains unionized in stomach for better absorption. 
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3. Drugs having reduced solubility at higher pH, e.g. Rosiglitazone maleate, captopril and
chordiazepoxide. 
4. Local action as it seen in the treatment of Helicobacter pylori by Amoxicillin. 
5. The  bioavailability  of  drugs  that  get  degraded  in  alkaline  pH  can  be  increased  by
formulating gastro-retentive dosage forms, e.g. Doxifluridine, which degrades in small
intestine.
6. To minimize gastric irritation this may be sudden increase of drug concentration in the
stomach, e.g. NSAID. 
Limitations of FDDS42 
1. The residence time in the stomach depends upon the digestive state. Hence, FDDS should
be administered after the meal. 
2. The ability to float relies in the hydration state of the dosage form. In order to keep these
tablets floating In vivo, intermittent administration of water (a tumbler full, every 2 hrs) is
beneficial. 
3. The ability of drug to remain in the stomach depends upon the subject being positioned
upright. 
4. FDDS are not  suitable for  the drugs  that  have solubility or  stability problems in the
gastric fluid. 
5. Drug like Nifedipine is well absorbed along the entire GIT and undergoes significant first
pass metabolism, but  it  is  not  a desirable candidate for FDDS since the slow gastric
emptying may lead to the reduced systemic bio-availability. 
Application of FDDS42 
1. Recent study indicated that  the administration of diltiazem floating tablets twice a day
might be more effective compared to normal tablets in controlling the blood pressure of
hypertensive patients. 
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2. Modapar® HBS containing L-DOPA and Benserazide, here the drug was absorbed over a
period  of  6-8  hrs  and  maintained  substantial  plasma  concentration  for  Parkinsonian
patients. Cytotech® containing Misoprostol, a synthetic prostaglandin–EL analogue, for
prevention of gastric ulcer caused by non-steroidal anti-inflammatory drugs (NSAIDS).4 
3. Site specific drug delivery: These systems are particularly advantageous for drugs that are
specifically  absorbed  from  stomach  or  the  proximal  part  of  the  small  intestine,  e.g.,
Riboflavin and Furosemide. 
4. FDDS also serves as an excellent drug delivery system for the eradication of Helicobacter
pylori, which causes chronic gastritis and peptic ulcers. 
5. Developing HBS dosage form for Tacrin provide better delivery systems and reduced its GI
side effects. 
6. Treatment of gastric and duodenal ulcer.
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Literature review
Literature review for understanding the study was done by referring to various  national  and
international  journals,  published  articles  in  various  official  standard  books  and  referring  to
various websites.
 K.Karunakar et.  al  71., prepare and evaluate floating drug delivery system of Lamivudine.
Floating matrix  tablets of Lamivudine were developed to prolong gastric residence time and
increase its bioavailability. Rapid gastrointestinal transit could result in incomplete drug release
from the drug delivery system above the absorption zone leading to diminished efficacy of the
administered dose. The tablets were prepared by direct compression technique, using polymers
such  as  hydroxyl  propyl  methyl  cellulose  (HPMC E15),  Ethyl  cellulose  and  Xanthan  gum
combination  and  other  standard  excipients.  Sodium bicarbonate  was  incorporated  as  a  gas-
generating agent. The effects of different concentrations of HPMC, EC and Xanthan gum on
drug  release  profile  and  floating  properties  were  investigated.  Comparable  release  profiles
between the  commercial  product  and the  designed  system were  obtained.  The  model  fitting
showed that the optimized formulation F2 formulations followed Korsmeyer and Peppas model,
which had a higher value of correlation coefficient (r). While tablet hardness had little or no
effect  on the  release kinetics  and  was found to  be a  determining factor  with  regards  to  the
buoyancy of the tablets.
Varun  Dasari  et.  al72.,  Formulation  of  potent  drug  molecules  as  dosage  form  still  draws
continuous interest and challenges against its optimization towards pharmacokinetics parameters
like absorption, bioavailability, onset of action, duration of action Besides it has been proved that
by increasing gastric retention time will increase the drug absorption effectively..Lamivudine is
an potential anti-HIV agent, used for the long term treatment of HIV-1 infection.It is approved by
the U.S Food and Drug Administration (FDA). The dissolution characteristics of optimized multi
unit  formulation  MF8  is  compared  with  that  of  the  pure  drug  and  Marketed  formulation
(EPIVIR).  Compatibility  among  the  drug  and  optimized  polymer  i.e.,  Geleol  Pastilles  was
assessed by performing IR spectroscopy studies Characteristics with the aid of Geleol Pastilles as
polymer. , very promising in vitro results were observed with multi unit floating formulations of
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Lamivudine, further there is a scope to conduct the bioavailability studies in human volunteers to
know the exact pharmacokinetics of the developed multi unit GFDDS of Lamivudine.
Ichikawa  et  al  43 developed  a  new  multiple  type  of  floating  dosage  system  composed  of
effervescent layers and swellable membrane layers coated on sustained release pills. The inner
layer of effervescent agents containing sodium bicarbonate and tartaric acid was divided into 2
sublayers to avoid direct contact between the 2 agents. These sublayers were surrounded by a
swellable  polymer  membrane  containing  polyvinyl  acetate  and  purified  shellac.  When  this
system was immersed in the buffer at 37ºC, it settled down and the solution permeated into the
effervescent  layer  through  the  outer  swellable  membrane.  CO2  was  generated  by  the
neutralization reaction between the 2 effervescent agents, producing swollen pills (like balloons)
with  a  density  less  than  1.0  g/mL.  It  was  found  that  the  system had  good  floating  ability
independent of pH and viscosity and the drug (Para-amino benzoic acid) released in a sustained
manner (Figure 1, A and B). 
Stock well et al44  prepared floating capsules by filling with a mixture of sodium alginate and
sodium bicarbonate. The systems float during in vitro tests as a result of the generation of CO2
that  was  trapped  in  the  hydrating  gel  network  on  exposure  to  an  acidic  environment.  The
carbonates also provide the initial alkaline microenvironment for polymers to gel. Moreover, the
release of CO 2 helps to accelerate the hydration of the floating tablets, which is essential for the
formation of a bioadhesive hydrogel. This provides an additional mechanism (‘bioadhesion’) for
retaining the dosage form in the stomach, apart from floatation. Floating dosage forms with an in
situ gas generating mechanism are expected to have grater buoyancy and improved drug release
characteristics.  However,  the  optimization  of  the  drug  release  may alter  the  buoyancy  and,
therefore, it is sometimes necessary to separate the control of buoyancy from that of drug release
kinetics during formulation optimization. 
Yang et al 45 developed a swellable asymmetric triple-layer tablet with floating ability to prolong
the  gastric  residence  time  of  triple  drug  regimen  (tetracycline,  metronidazole,  and
clarithromycin)  in  Helicobacter  pylori–associated  peptic  ulcers  using hydroxy propyl  methyl
cellulose (HPMC) and poly (ethylene oxide) (PEO) as the rate-controllingpolymeric membrane
excipients. The design of the delivery system was based on the swellable asymmetric triple-layer
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tablet approach. Hydroxypropylmethylcellulose and poly (ethylene oxide) were the major rate-
controlling polymeric excipients. Tetracycline and metronidazole were incorporated into the core
layer of the triple-layer matrix for controlled delivery, while bismuth salt was included in one of
the outer layers  for instant  release.  The floatation was accomplished by incorporating a gas-
generating layer consisting of sodium bicarbonate: calcium carbonate (1:2 ratios) along with the
polymers.  The  in  vitro  results  revealed  that  the  sustained  delivery  of  tetracycline  and
metronidazole over 6 to 8 hours could be achieved while the tablet remained afloat. The floating
feature aided in prolonging the gastric residence time of this system to maintain high-localized
concentration of tetracycline and metronidazole.
Fahan  Jalees  ahmed46 et  al.,  Development  and  Evaluation  of  Floating  Matrix  Tablets  of
Acyclovir October – December 2011 RJPBCS Volume 2 Issue 4 Page No. 547 Acyclovir [9-(2-
hydroxyethoxymethyl) guanine] is an acyclic nucleoside analogue of guanosine that is a potent
and  selective  antiviral  agent.  It  has  a  relatively  short  plasma  half-life  (3  hr).  When  orally
administered,  it  is  slowly and  scarcely absorbed  from the  gastrointestinal  tract.  The  plasma
concentration reaches its therapeutic level in 1.5 to 2 hr. The short biological half life of drug
favors the development of a sustained release formulation which retain in the stomach for  a
prolonged period of time.The present work emphasis on the study of dissolution studies and in
vitro buoyancy of acyclovir floating system.
A. M Mahale et al,  formulation and  in-vitro  evaluation of  gastroretentive drug delivery
system for acyclovir. International journal of comprehensive Pharmacy, DOI : 2011 47
    Floating matrix tablets of acyclovir were developed to prolong gastric residence time and
increase its bioavailability.  The tablets were prepared by direct  compression technique,  using
polymers  such  as  Hydroxypropylmethylcellulose  (HPMC,  Methocel  K100M),  Carbopol  and
Sodium alginate alone or in combination. Sodium bicarbonate and Citric acid was incorporated
as a gas-generating agent. All the tablets passed the compendial tests and other tests like weight
variation, drug content, hardness, friability. The floating time was found to be more than 12 hrs.
All the tablets showed the floating lag time of less than 10 minute.
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    T. Akelesh et al. Formulation development of gastro retentive floating tablet of  acyclovir
using natural gums, Scholars Research Library,2011,3(1): 254-26148.
    Floating  tablets  of  Acyclovir  was  developed  by  using  gas  forming  agents  like  sodium
bicarbonate  and natural  gums like Locust  bean gum, Sodium alginate  and  Xanthan  gum by
effervescent technique. Various combinations of floating polymers were used in this formulation.
The floating tablets were evaluated for uniformity of weight, hardness, friability, drug content, in
vitro buoyance, and buoyancy lag time and dissolution studies. The formulation optimized for
different  concentration of natural  gums like Locust  bean gum, Sodium alginate and Xanthan
gum.
     J. Padmavathy et al,  Formulation and evaluation of ofloxacin floating tablets using
HPMC, International Journal of Pharmacy and Pharmaceutical Sciences, Vol 3, Issue 1,
201149
     The present study outlines a systematic approach for designing and development of Ofloxacin
floating tablets  to enhance  the bioavailability and therapeutic  efficacy of  the drug.  Different
formulations were formulated by wet granulation technique using HPMC K4M, HPMC K15M
and  HPMC  K100M  (floating  agent)  as  polymers  along  with  sodium  bicarbonate  as  gas
generating  agent.  The  formulations  were  evaluated  for  their  physicochemical  properties,
buoyancy lag time, total floating time, swelling index and invitrodrug release. It was found that
the  hardness  of  the  tablets  affects  the  Buoyancy  characteristic  of  the  dosage  form.  All  six
formulations possessed good floating properties with total floating time between 8 – 12 hrs.
Jaimini Manish et. al.50, delayed release tablets of Losartan Potassium were formulated using
two different grades of methocel K100 and K15 by effervescent technique. Sodium bi carbonate
was employed as gas generating agent. Tablets prepared by wet granulation method were further
evaluated  for  hardness,  friability,  weight  variation,  drug  content,  in-vitro  buoyancy  and
dissolution studies. All the prepared tablets showed good in-vitro buoyancy. The effect of citric
acid and two different grades of methocel on drug release profile and floating property were
investigated.
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Kumar.et. al.51developed floating tablets of metformin hydrochloride and evaluated for increase
bioavailability by increasing gastric residence time and sustained release of drug on the upper
part of gastrointestinal tract thereby diminishing side effects and enhanced patient compliance.
Metformin hydrochloride, an oral anti-diabetic having narrow absorption window in the upper
part of gastrointestinal tract, was formulated as floating matrix tablet using gas generating agent
(potassium  bicarbonate)  and  hydrophilic  gelling  polymer  hydroxyl  propyl  methyl  cellulose
(hypromellose)  by wet  granulation technique.  The  prepared  formulations  were  evaluated  for
floating time and in-vitro drug release studies by modified dissolution method.
Chodavarapuet  al 52.,  investigated  that  the  effectiveness  of  the  edible  gum  of
Abelmoschusesculentus as a polymer in the development of a gastric floating dosage form of
metformin HCl.  Abelmoschusesculentus,  popularly known as  okra,  was  shown to  aid  in  the
formulation of floating tablets. In the present study, it was used as a pharmaceutical excipient
along with HPMC E15 in the formulation of floating tablets. The prepared tablets were tested for
physicochemical  properties,  drug content  uniformity,  in-vitro drug release patterns and FT-IR
spectral  analysis.  From the  study,  it  was   evident   that  the   formulations   which  included
abelmoschusesculentus  gum  (F1,  F3,  and  F4)  have  lesser   floating   capacity   but  show  a
sustained  release of drug whereas the formulation (F2) which  contained only HPMC has higher
floating capacity but poor sustained release of drug. The formulation of okra gum manifested a
prolonged release of the activeingredients.
Kshirsagaret al53.,have developed a hydro dynamically balanced system of metformin as a single
unit floating tablet. Various grades of low‐density polymers were used for the formulation of this
system. They prepared by physical blending of metformin and the polymers in varying ratios.
The  formulation  was  optimized  on  the  basis  of  in-vitro buoyancy  and  in-vitro release  in
simulated gastric fluid pH 1.2. Tablets prepared with HPMC K15M and carbopol showed best
in-vitro percentage release and selected as a optimize formulation. All the formulations were
robust tablets with optimum hardness, consistent weight uniformity with low tablet friability. In-
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vitro drug release  tests  of  the tablets  indicated  the  sustained release  of  metformin  HCl was
reported.
Narayanet al54.,have formulated the salbutamol sulphate as a floating matrix tablets and control
the drug release up to 24 h for administration as once daily dose. Salbutamol sulphate is a short
acting bronchodilators which have short biological half life about 2-4 h. Floating matrix tablets
were  formulated  by  using  swelling  polymer  like  methylcellulose,  hydroxy  propyl  methyl
cellulose  (K100M,  K4M) with  different  concentrations  in  the  preparation  of  floating matrix
tablets.  Their  formulation  variables  like  hardness,  polymer  concentrations,  and  shape  of  the
tablets were optimized to achieve the floating nature of the tablet in stomach for 24 h. In addition
stearic acid is included in this formulation to evaluated release characteristics.
Liandong et al55.,have developed the dextromethorphan hydrobromide sustained-release (DMB-
SR)  tablets  using  floating  technique  to  prolong  the  gastric  residence  time  and  compared
pharmacokinetic behaviour with conventional sustained release tablets. DMB-SR floating tablets
wereprepared  employing  hydroxypropyl  methylcellulose  as  hydrophilic  gel  material,  sodium
bicarbonateas gas-generating agent and hexadecanol as floating assistant agent. An orthogonal
experimentdesign method was used to select the optimized formulation. The floating tablets were
evaluated foruniformity of weight, hardness, friability, drug content, floating characteristics, in-
vitro release and in-vivo bioavailability.
Varmaet al.56,have developed sustained release gastroretentive dosage forms which were enabled
to  prolong  the  drug  input  to  the  upper  parts  of  gastrointestinal  tract  and  improve  the
bioavailability  of  medication  that  is  characterized by narrow absorption window. Metformin
hydrochloride was selected as a model drug because of poor absorption from low GI tract and
less bioavailability above 50%. Hydroxy propyl methyl cellulose (HPMC K4M) and carbopol
934P were used as polymers and sodium bicarbonate as gas generating agent to reduce floating
lag time. Tablets were prepared by wet granulation method. Floating tablets were evaluated for
hardness,  friability,  weight  variation,  drug  content,  floating  properties  and  in-vitro release
pattern. The in-vitro drug release followed first order kinetics and drug release was found to be
diffusion controlled.
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Deshpande et al.  57(Deshpande et al., 1997a; Deshpande et al., 1997b) developed a controlled-
release gastric  retention system composed of  a  swellable  core,  which consisted of  the  drug,
chlorphenamine  maleate  or  riboflavin  5′  phosphate,  and  the  expanding  agents  polyvinyl
pyrrolidone (PVP), Carbopol 934P and calcium carbonate. The tablet core was coated with a
permeable coating, consisting of blends of Eudragit RL® 30 D and NE 30 D in different ratios.
The tablets swelled to 2- 4 times their original volume, while releasing the drug in a controlled
manner. The optimal ratio of Eudragit® RL 30 D: NE 30 D was found to be 70: 30, which was
optimum  for  sufficient  elasticity  to  withstand  the  pressure  of  expansion  during  the  initial
swelling phase, and allowing the breakdown of the tablet following release of the drug. 
Shalaby  et  al.58described  enzyme-digestible  hydrogels  consisting  of  poly(vinyl  pyrrolidone)
crosslinked  with  albumin  (Shalaby  et  al.,  1992;  Shalaby  and  Park,  1990).  These
gastroretentivehydrogels, swelled to a significant extent depending on the albumin content and
degree of albumin alkylation and were degraded in the presence of pepsin. Even under fasted
conditions,  the gastric  residence time in dogs exceeded 24 h.  These hydrogels  were used to
deliver flavin mononucleotide, which is known to be absorbed only from the upper part of the
small intestine, where the drug could be detected up to 50 h after administration in the blood,
suggesting its efficient retention in the stomach.  
Omidianet al.59developed superporous hydrogel hybrids, which are prepared by crosslinking a
water-soluble or water-dispersible polymer to the formed superporous hydrogel (Omidian et al.,
2005; Omidian et al., 2006). Examples for hybrid agents are polysaccharides, such as sodium
alginate,  pectin,  chitosan  or  synthetic  water-soluble  hydrophilic  polymers,  e.g.  poly(vinyl
alcohol).  Unlike  superporous  hydrogels  and  superporous  hydrogel  composites,  superporous
hydrogel hybrids are not easily breakable when stretched due to their highly elastic properties in
the swollen state, which may be very useful for developing gastrointestinal DDS. 
Yuasa et al.60(Yuasa et al., 1996) developed intragastric floating and sustained release granules
of diclofenac sodium using a polymer solution of HPC-L grade and EC, and calcium silicate as a
floating carrier,  which has a characteristically porous structure. The coated granules acquired
floating ability from the air trapped in the pores of calcium silicate when they were coated with a
polymer. 
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Whitehead et al.61(Whitehead et al., 1996) developed multiple unit floating freeze dried calcium
alginate beads. These beads maintained a positive floating force for over 12 h, and the density
measurement, using a helium pycnometer, was less than 1 g/cm. The  in vivo  behavior of this
system  compared  to  non-floating  multiple-unit  dosage  forms  manufactured  from  identical
material have also been performed using γ-scintigraphy in the fed state (Whitehead et al., 1998).
Prolonged gastric residence times of over 5.5 h were achieved for the floating formulations,
while the non-floating beads displayed short gastric residence times, with a mean onset emptying
time of 1 h.This approach provides floating drug delivery systems based on the formation of
CO2 gas. It utilizes effervescent components such as sodium bicarbonate (NaHCO3) or sodium
carbonate, and additionally citric or tartaric acid (Rubinstein and Friend, 1994). Alternatively
matrices containing chambers of liquids that gasify at body temperature could be used (Michaels,
1975;  Micheals,  1974;  Ritschel,  1991).  Upon  contact  with  the  acidic  environment,  a  gas  is
liberated, which produces an upward motion of the dosage form and maintains its buoyancy. A
decrease in specific gravity causes the dosage form to float on the chyme.
Gröning et  al62(Gröning et  al.,  2007; Groning et  al.,  2006) developed gastroretentive dosage
forms prepared from compressed collagen sponges. The sponges were manufactured by freeze-
drying a riboflavin-containing collagen solution. The precompressed collagen was transported
into  a  tablet  machine  for  tablet  compression.  A second type  of  tablet  was  manufactured  by
combining  compressed  collagen  sponges  with  hydrophilic  matrix  layers  of  hydroxypropyl
methylcellulose  (HPMC)  containing  captopril  or  acyclovir  into  a  bilayer  tablet.  Following
contact with aqueous fluids, the collagen sponge expanded to a large size. Both systems released
the drug in a controlled manner.  In vivo studies on riboflavin tablets have shown that the drug
was absorbed for a long time period.
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AIM
1.  The basic  goal  of  therapy is  to  achieve  a  steady state  blood level  that  is  therapeutically
effective and non-toxic for an extended period of time. The design of proper dosage regimens is
an important element in accomplishing this goal.
2. Floating tablets are drug delivery systems that are designed to achieve a prolonged therapeutic
effect by continuously releasing medication over an extended period of time after administration
of single dose in stomach region.
3. The main aim is to Formulate and Evaluate Floating tablets of Lamuvudine using various
hydrophilic polymers.
Objective of the study:
The present study is planned with the following objectives:
 To prepare Lamuvudine floating tablets.
 To improve the floating time of the tablet.
 To prepare tablets by direct compression method.
 To investigate the pre  compression & post  compression parameters  of  the  developed
formulations.
 In-vitro characterization of the developed floating tablets.
 To determine the In-vitro drug release studies.
32
PLAN OF WORK
I. Literature survey
II. Pre-formulation studies
a) Pre-formulation study of Lamuvudine
b) Organoleptic Properties
c) Melting point of drug
d) Determination of solubility
e) Drug-Excipient compatibility studies
III. Evaluation of blends
a) Bulk density
b) Tapped density
c) Angle of repose
d) Carr’s Index (Compressibility Index)
e) Hausner’s Ratio
IV. Preparation of Floating tablets by using various concentrations of Polymers
• Direct compression Technique.
V. Evaluation of Matrix tablets
• Thickness
• Hardness
• Weight variation
• Friability
• Buoyancy test (Floating time)
• In-vitro drug release study
• Assay
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DRUG PROFILE63, 64
Lamivudine:  A reverse transcriptase inhibitor  and  zalcitabine analog in  which a sulfur  atom
replaces the 3' carbon of the pentose ring. It  is used to treat Human Immunodeficiency Virus
Type 1 (HIV-1) and hepatitis B (HBV).
Structure
Structure of Lamivudine
Chemical name:
4-amino-1-[(2R, 5S)-2-(hydroxymethyl)-1, 3-oxathiolan-5-yl]-1,2 dihydropyrimidin-2-one 
Molecular formula: C8H11N3O3S
Molecular weight: 229.25
Category: Antiretroviral (Nucleoside Reverse Transcriptase Inhibitor). 
Biological profile 
Mechanism of action 
Lamivudine is a synthetic nucleoside analogue and is phosphorylated intracellularly to its active
5'-triphosphate  metabolite,  lamivudine  triphosphate  (L-TP).  This  nucleoside  analogue  is
incorporated into viral DNA by HIV reverse transcriptase and HBV polymerase,  resulting in
DNA chain termination. 
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Pharmacokinetics:
Absorption: Rapidly absorbed, food effects on absorption T max – 0.9 ± 0.3 hrs in fasted state,
3.2 ± 1.3 hrs in fed state, there is no significant difference in systemic exposure (AUC) in the fed
and fasted states. Absolute bioavailability: about 86% (range 86 ± 16%).
Distribution: Volume of  distribution  (Vd)  oral:  1.3  ±  0.4  L/kg  (range  12-14  L/kg).  protein
binding: < 36%. The single- and multiple dose Pharmacokinetics of Lamivudine are linear and
dose proportional  in  a  dose range  of  10 to  60 mg/day.  Steady-state  achieved in  1-2 weeks.
Average plasma concentration is about 83 ng/mL (n=114) with a range from 30 to 200 ng/mL.
Metabolism: Approximately  70%  of  an  intravenous  dose  of  Lamivudine  is  recovered  as
unchanged  drug  in  the  urine.  In  humans,  the  only  known  metabolite  is  the  trans-sulfoxide
metabolite Approximately 70% of the administered dose is excreted slowly in the urine, reaching
a peak 7 to 10 hours after administration. Metabolites are detectable in the urine 120 hours after
administration. Faecal elimination accounts for approximately 11 % of the administered dose.
Lamivudine is usually completely eliminated within 144 hours post dose.
Excretion:  Elimination half-life: 5 to 7 hours. The systemic clearance is 0.33±0.06 L/hr/kg.
Elimination via the kidneys; approximately 5.2% ± 1.4% (range 5.1272 – 5.2728) of the daily
dose is excreted in urine as unchanged Lamivudine.
Indication           :    For the treatment of HIV infection and chronic hepatitis B (HBV). 
Dosage               :    For adults with HIV (or children over 12), the dose is 300mg once daily, or
150mg twice a day. Lamivudine is never used on its own in the treatment of HIV.
For the treatment of adults with hepatitis B, the dose is 100mg once daily. If co-infected with
HIV, then the dose is as for HIV.
For a child 3 months to 12 years old, about 1.4-2 mg per lb. of body weight twice a day, no more
than 150 mg per dose.
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1. Hypromellose 65, 66, 67:
Hypromellose is a semi synthetic, inert, viscoelastic polymer used as anophthalmic lubricant, as
well as an excipient and controlled-delivery component in oral medicaments. Hypromellose is a
partly O-methylated and O-(2-hydroxypropylated) cellulose.
Structural formula:
Synonyms: BenecelHydroxypropylmethylcellulose (HPMC), Methocel, Metolose.
Description: Odorless and tasteless, white or creamy-white fibrous or granular powder.
Acidity/alkalinity: pH = 5.5–8.0 for a 1% w/w aqueous solution.
Density (true): 1.326g/cm3.
Stability: Stable material, although it is hygroscopic after drying.
Viscosity: Ranges from 3-1, 00,000 cps.
Egs: Metolose 60SH, Metolose 65SH, Metolose 90 SH etc.
Functional Category
Coating  agent;  film-former;  rate-controlling polymer  for  sustained  release;  stabilizing  agent;
suspending agent; tablet binder; viscosity-increasing agent.
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Solubility:
Soluble in cold water, forming a viscous colloidal solution; practically insoluble inchloroform,
ethanol (95%), and ether, but soluble in mixtures of ethanol anddichloromethane, mixtures of
methanol  and  dichloromethane,  and  mixtures  of  water  andalcohol.  Certain  grades  of
hypromellose are soluble in aqueous acetone solutions, mixtures ofdichloromethane and propan-
2-ol, and other organic solvents.
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Safety:  Non-toxic  and  non-irritant  material,  although  excessive  oralConsumptionmayhave  a
laxative effect.
Applications:
 As a tablet binder and as a matrix for use in extended-release tabletformulations.
 As a film forming agent at the concentrations of 2–20% w/w to coat thetablets.
 As an emulsifier, suspending agent, and stabilizing agent in topical gelsandointments.
 As  a  protective  colloid,  it  can  prevent  droplets  and  particles  from  coalescing
oragglomeratingthus inhibiting the formation of sediments.
 As  a  thickening  agent  (0.45–1.0%  w/w),  vehicles  for  eye  drops  and  artificialtear
solutions.
 In addition, it is used in the manufacture of capsules, as an adhesive in plasticbandages
and asa wetting agent for hard contact lenses. It is also widely usedin cosmetics and food
products.
SODIUM BICARBONATE:
Baking soda usually appears  as  a  fine  powder,  but  can also appear  as  a  white  solid  that  is
crystalline. Ancients Egyptians used natural deposits of Natron, a mixture of sodium carbonate
and sodium bicarbonate,  as a cleansing agent  like soap for a  variety of  purposes. In  1791 a
French Chemist  produced sodium bicarbonate as we know it  today.  In  1846, two New York
bakers developed the process of making sodium bicarbonate and carbon dioxide into baking soda
to help dough to rise quicker and more efficiently. Each of them started a company on their own,
but later merged and became the makers of Arm & Hammer baking soda.
Summary: We are finding new uses for baking soda all the time, and here are just a few. 
• A paste can be made that is very effective in cleaning and scrubbing.
• It  has  long been  used  as  a  natural  tooth whitening agent.  It  has  been  used as  a  dry
chemical for fire extinguishers. 
• Antiquarian booksellers use it to absorb and remove the musty odor of older books. 
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• Everyone at one time or another has had a box of it in their refrigerator to help absorb
odor. 
• It adds a smooth texture to creams and lotions. 
• It acts as a pH stabilizer
Precautions
People on sodium reduced diets should check with a doctor before consuming baking soda.
Citric Acid Monohydrate
1. Nonproprietary Names
• BP: Citric acid monohydrate
• JP: Citric acid
• PhEur: Acidumcitricummonohydricum
• USP: Citric acid
2. Synonyms E330; 2-hydroxypropane-1,2,3-tricarboxylic acid monohydrate.
3.  Chemical  Name and CAS  Registry  Number  2-Hydroxy-1,2,3-propanetricarboxylic  acid
monohydrate [5949-29-1]
4. Empirical Formula and Molecular Weight C6H8O7·H2O 210.14
5. Structural Formula
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6. Functional Category
Acidifying agent; antioxidant; buffering agent; chelating agent; flavor enhancer.
7. Applications in Pharmaceutical Formulation or Technology
Citric acid (as either the monohydrate or anhydrous material) is widely used inpharmaceutical
formulations and food products, primarily to adjust the pH of solutions. It  hasalso been used
experimentally  to  adjust  the  pH  of  tablet  matrices  in  enteric-coatedformulations  for  colon-
specific  drug  delivery.1  Citric  acid  monohydrate  is  used  in  thepreparation  of  effervescent
granules, while anhydrous citric acid is widely used in thepreparation of effervescent tablets.
Citric  acid  has  also  been  shown  to  improve  the  stabilityof  spray-dried  insulin  powder  in
inhalation formulations.In  food products,  citric  acid is  used as  a  flavor  enhancer  for  its  tart,
acidic taste. Citric acidmonohydrate is used as a sequestering agent and antioxidant synergist. It
is also a component of anticoagulant citrate solutions. Therapeutically, preparations containing
citricacid have been used to dissolve renal calculi.
8. Description
Citric acid monohydrate occurs as colorless or translucent crystals, or as a white crystalline,
efflorescent  powder.  It  is  odorless  and  has  a  strong  acidic  taste.  The  crystal  structure  is
orthorhombic.
MICROCRYSTALLINE CELLULOSE 68, 69
Synonyms: Avicel PH, Celex, Cellulose gel, Celphere, Ceolus KG, Emcocel, Ethisphere, Fibro-
cel, Pharmacel, Tabulose. 
Description: 
It is a white, odourless, tasteless, extra free flowing powder which is relatively free from organic
and  non-organic  contaminants.  It  is  metabolically  inert,  and  has  excellent  water  absorptive,
swelling & dispersion properties, is insoluble in water, dilute acid, common organic solvents and
oils. It is partially soluble in dilute alkali. 
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Solubility:
Slightly soluble in 5%w/v sodium hydroxide solution. PracticallyInsoluble in water, dilute acids
and most organic solvents. 
Applications in Pharmaceutical Technology: 
• MCC is widely used in pharmaceuticals primarily as a binder / Diluent in oral tablet and
capsule  formulations  where  it  is  used  in  both  wet  granulation  and  direct  compression
processes (20-90%). 
• In addition to its use as binder/diluents, microcrystalline cellulose also has some lubricant
and disintegrating properties that make it useful in tableting. 
• It is used in cosmetics and food products.
MAGNESIUM STEARATE
Synonyms: Magnesium  octadecananoate,  Octadecanoic  acid,  Magnesium  salt,  stearic  acid
magnesium salt.
Description: Magnesium stearate is a fine, white, precipitated or milled, Impalpable powder of
low bulk density, having a faint odor or and a characteristic taste. The powder is greasy to the
touch and readily adheres to the skin. 
Solubility: Practically insoluble in ethanol, ethanol (95%), ether and Water, slightly soluble in
warm benzene and warm ethanol (95%). 
Applications in Pharmaceutical Technology: 
• Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical formulations.  
• It is primarily used as a lubricant in capsule and  tablet manufacture at 
• Concentrations between 0.25 and 5%w/w. It is also used in barrier creams.
INSTRUMENTS DETAILS
S.NO EQUIPMENT NAME SOURCE
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1
DIGITAL WEIGHING
MACHINE
SHIMADZU ATY 244
2
TABLET COMPRESSION
MACHINE
KARNAVATHI
MINI PRESS-II
3 PFIZER HARDNESS TESTER
CINTEX IND. CORPORATION,
MUMBAI
4 FRIABILITY TESTER ELECTROLAB PVT LTD. INDIA
5
USP DISSOLUTION
APPARATUS
LAB INDIA DS 8000
6 TRAY DRYER SISCO
7
UV-VIS DOUBLE BEAM
SPECTROPHOTOMETER
ELICO SL 164 DOUBLE BEAM
SPECTROPHOTOMETER
INGREDIENT DETAILS
S.N
O
DRUG/EXCIPIENTS NAME OF SUPPLIER
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1 LAMUVUDINE ALKEM PVT MUMBAI
2 HPMC E15 COLORCON
3 HPMC K15M COLORCON
4 SODIUM BI CARBONATE SD FINE –CHEM PVT, MUMBAI
5 CITRIC ACID SD FINE –CHEM PVT, MUMBAI
6
MICROCRYSTALLINE
CELLULOSE
SD FINE –CHEM PVT, MUMBAI
7 MAGNESIUM STEARATE SD FINE –CHEM PVT, MUMBAI
8 TALC SD FINE –CHEM PVT, MUMBAI
METHODOLOGY
Colour, odor, taste and appearance:
The color, odor and taste of the drug were recorded using descriptive terminology. 
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Melting point determination: 
Melting point of the drug sample was determined by capillary method by using melting point
apparatus. The reported and observed melting point is shown in Table.
Determination of solubility:
The  solubility of  the  Lamuvudine  was  determined  by adding excess  amount  of  drug in  the
solvent and equilibrium solubility was determined by taking supernatant and analyzing it on Lab
India, double beam spectrophotometer.  The reported and observed melting point is  shown in
Table.
% solubility = sample absorbance /standard absorbance × dilution factor ×100
Fourier Transformation Infra-red (FTIR) analysis:
Infra-red  spectroscopy  analysis  was  performed  by  Fourier  Transformation  Infrared
Spectrophotometer Alpha Brooker FTIR (Tokyo, Japan).The instrument was calibrated by using
polystyrene film.
Ultraviolet Visible (UV-visible) spectroscopy: 
Construction of Calibration curve of model drugs by UV-Visible spectroscopy:
 Preparation of Standard stock solutions:
Lamuvudine equivalent  to 100 mg was weighed and transferred to 100 ml volumetric  flask,
dissolved in methanol and the final volume was made upto 100ml with 0.1N HCL. The resulted
solution had the concentration of 1mg/ml (1000µg/ml) which was labeled as “stock solution A”.
 From the stock solution A, 1 ml was pipette out in 10ml volumetric flask and the final
volume was made upto 10ml with 0.1N HCL. The resulted solution had the concentration of
0.1mg/ml (100µg/ml) which was labeled as “stock solution B”. This stock solution B is used as
working stock solution for further study. Further dilutions were prepared from the same solution. 
Preparation of Standard solutions:
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              From the stock solution B, further dilution was made with 0.1N HCL in 10 ml
volumetric flasks to get the solutions in the range of 2-10 µg/ml concentration and absorbance
was  recorded  at  280  nm  against  suitable  blank  using  UV-Spectrophotometer  (UV-1601,
Shimadzu, Japan).A calibration curve of absorbance against concentration was plotted and the
drug  follows  the  Beer’s  &  Lambert’s  law  in  the  concentration  range  of  2-10µg/ml.  The
Regression equation and correlation coefficient was determined. 
Evaluation of Blend:
Angle of Repose: 
The flow property was determined by measuring the Angle of Repose. In order to determine the
flow property,  the  Angle  of  Repose  was  determined.  It  is  the  maximum angle  that  can  be
obtained between the free standing surface of a powder heap and the horizontal. 
                                                 Angle of repose= tan-¹ (h/r) 
                                                 Where, h = height r = radius 
Procedure: 
 20gms of the sample was taken 
 The sample was passed through the funnel slowly to form a heap. 
 The height of the powder heap formed was measured. 
 The circumference formed was drawn with a pencil on the graph paper. 
The radius was measured and the angle of repose was determined. This was repeated three times
for a sample. 
Bulk density: 
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Bulk density is ratio of given mass of powder and its bulk volume. Bulk density was determined
by measuring the volume of known mass of powder sample that has been passed through the
screen in to graduated cylinder or through volume measuring apparatus in to cup. 
 Bulk density = M / V0 
 Where M= mass of the powder; V0=bulk volume of the powder. 
Tapped density: 
 A known quantity of powder was transferred to a graduated cylinder and volume V0 was noted.
The cylinder fixed to a density determination apparatus, tapped for 200 times then reading was
observed. The density is achieved by mechanically tapped by a measuring cylinder containing
the powder sample. After observing the initial volume the cylinder is mechanically tapped and
volume reading were taken until little further volume changes is observed. 
                                                                 Tap density = M / Vr
 Where M = mass of the powder, Vr = final tapping volume of the powder. 
Compressibility index and Hausner ratio: 
Basic methods for the determination of compressibility index and Hausner ratio:
While there are some variations in the method of determining the compressibility index and
Hausner ratio, the basic procedure is to measure the unsettled apparent volume,(VO), and the
final  tapped volume,  (Vf),  of  the  powder  after  tapping the  material  until  no  further  volume
changes occur. The compressibility index and the Hausner ratio are calculated as follows: 
 Compressibility index = 100 × Vo-Vf/Vo 
Hausner ratio = Vo/Vf
 Where, Vo = apparent volume, Vf= final tapped volume. Alternatively, the compressibility index
and hausner ratio may be calculated using measuredvalues of bulk density and tapped density as
follows: 
Compressibility index = 100 ×{ tapped density - bulk density / bulk density}
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Hausner ratio = tapped density / bulk density 
In a variation of these methods, the rate of consolidation is sometimes measured rather than, or in
addition to, the change in volume that occurs on tapping. For the compressibility index and the
hausner ratio, the generally accepted scale of flow ability is described in the following table. 
Flow properties and corresponding Angle of repose, Compressibility index and Hausner ratio:
Table 5: Flow properties determination
S. No Flow properties Angleof
repose(θ)
Compressibility
Index (%)
Hausner ratio
1 Excellent 25-30 <10 1.00-1.11
2 Good 31-35 11-15 1.12-1.18
3 Fair 36-40 16-20 1.19-1.25
4 Passable 41-45 21-25 1.26-1.34
5 Poor 46-55 26-31 1.35-1.45
6 Very poor 56-65 32-37 1.46-1.59
7 Very very poor > 66 >38 >1.6
EVALUATION OF TABLETS: 
The quantitative evaluation and assessment of a tablets chemical, physical and bioavailability
properties are important in the design of tablets and to monitor product quality. There are various
standards  that  have  been  set  in  the  various  pharmacopoeias  regarding  the  quality  of
pharmaceutical  tablets.  These  include  the  diameter,  size,  shape,  thickness,  weight,  hardness,
Friability, Buoyancy test and invitro-dissolution characters.
1. Physical Appearance: 
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The general appearance of a tablet, its identity and general elegance is essential for consumer
acceptance,  for control  of lot-to-lot  uniformity and tablet-to-tablet  uniformity.  The control  of
general  appearance  involves the measurement  of size,  shape,  colour,  presence or  absence of
odour, taste etc. 
2. Size& Shape:
It can be dimensionally described & controlled. The thickness of a tablet is only variables. Tablet
thickness  can  be  measured  by  micro-meter  or  by  other  device.  Tablet  thickness  should  be
controlled within a ± 5% variation of standard value. 
3. Weight variation test: 
This is an in process quality control test to ensure that the manufacturers control the variation in
the weight of the compressed tablets,  different  pharmacopoeia specify these weight variation
tests.. These tests are primarily based on the comparison of the weight of the individual tablets
(xi) of a sample of tablets with an upper and lower percentage limit of the observed sample
average (x-mean). The USP has provided limits for the average weight of uncoated compressed
tablets. These are applicable when the tablet contains 50mg or more of the drug substance or
when the latter comprises 50% or more, by weight of the dosage form. 
Method:
Twenty tablets were weighed individually and the average weight was calculated. The individual
tablet weights are then compared to the average weight. Not more than two tablets should differ
in their average weight by more than percentages stated in USP. No tablet must differ by more
than double the relevant percentage.
Table 6: Limits for Tablet Weight variation test: 
Average weight of tablet (mg) % Difference allowed
130 or less 10 %
From 130 to 324 7.5 %
> 324 5 %
4. Content Uniformity:
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The content  uniformity test  is  used to  ensure that  every tablet  contains  the amount  of  drug
substance intended with little variation among tablets within a batch. Due to increased awareness
of physiological availability, the content uniformity test has been included in the monographs of
all coated and uncoated tablets and all capsules intended for oral administration where the range
of size of the dosage form available include 50mg or smaller sizes. 
Method: 
Randomly select 30 tablets. 10 of these assayed individually. The Tablet pass the test if 9 of the
10 tablets must contain not less than 85% and not more than 115% of the  labeled drug content
and the 10th tablet may not contain less than 75% and more than 125% of the labeled content. If
these conditions are not met, remaining 20 tablets assayed individually and none may fall outside
of the 85 to 115% range.
Friability: 
Friction and shock are the forces that most often cause tablets to chip, cap or break. The friability
test  is  closely related to  tablet  hardness and designed to evaluate the ability of the tablet  to
withstand abrasion in packaging, handling and shipping. It is usually measured by the use of the
Roche friabilator. 
Method: 
A number of tablets are weighed and placed in the apparatus where they are exposed to rolling
and repeated shocks as they fall 6 inches in each turn within the apparatus. After four minutes of
this treatment or 100 revolutions,  the tablets are weighed and the weight compared with the
initial weight. The loss due to abrasion is a measure of the tablet friability. The value is expressed
as a percentage. A maximum weight loss of not more than 1% of the weight of the tablets being
tested during the friability test is considered generally acceptable and any broken or smashed
tablets are not picked. 
The percentage friability was determined by the formula: 
% friability = (W1-W2) / W1 X 100
 W1 = Weight of tablets before test 
 W2 = Weight of tablets after test
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Floating lag time:
The time between the introduction of the tablet into the medium and its rise to upper one third 
of the dissolution vesselis termed as floating lag time and the time for which the dosage form flo
ats is termed as the floating or flotation time. These tests are usually performed in simulated gast
ric fluid or 0.1NHCl maintained at 37 0C, by using USP dissolution apparatus containing 900 ml 
of 0.1N HCl as the dissolution medium.
 Drug release 
The drug release from the Lamuvudine tablets was investigated in a USP-II (paddle) apparatus,
900  ml  of  0.1N HCl  (50  rpm,  37°C).  At  predetermined  time  intervals,  5-ml  samples  were
withdrawn  and  take  1ml  sample  and  diluted  to  10  ml  and  then  analyzed  with  UV
spectrophotometry at λmax=280 nm.
Drug release kinetics70:
Dissolution  data  of  above  two  methods  was  fitted  in  Zero  order,  First  order  and  Higuchi
equations. The mechanism of drug release was determined by using Higuchi equation.
Zero-Order Kinetics:
Zero order as cumulative amount of Percentage drug released vs time
C = K 0 t
Where  K0 is the zero-order rate constant expressed in units of concentration/time and  t  is the
time in hours. A graph of concentration vs time would yield a straight line witha slope equal to
K0 and intercept the origin of the axes.
First order kinetics:
First order as log cumulative percentage of log (%) cumulative drug remaining vstime,
L o g C = L o g C o − k t / 2.303
Where C0is the initial concentration of drug, k is the first order constant, and t is the time.
Higuchi Model:
Higuchi’s model as cumulative percentage of drug released vs square root of time
Q = K t 1 / 2
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Where K is the constant reflecting the design variables of the system and t is the time in hours.
Hence, drug release rate is proportional to the reciprocal of the square root of time.
Korsmayer Peppas equations:
Korsmeyerpeppas equation used to determine the mechanism of drug release form the polymer
matrix of the tablet. Log cumulative percentage of drug released VS Logtime, and the exponent
n was calculated through the slope of the straight line.
M t / M ∞= K t n
Where  Mt/M_  is  the  fractional  solute  release,  t  is  the  release  time,  K  is  a  kinetic  constant
characteristic of the drug/polymer system, and n is an exponent that characterizes the mechanism
of release of tracers. For cylindrical matrix tablets, if the exponent n = 0.45, then the drug release
mechanism is  Fickian diffusion, and if  0.45 <n  < 0.89, then it  is  non-Fickian or anomalous
diffusion. An exponent value of  0.89 is  indicative of Case-II  Transport  or typical  zero-order
release.
Hixsoncrowell erosion equation:
Hixson-Crowell  cube  root  law,  as  the  cube  root  of  percentage  drug  remaining  vs.  time
correlated the release from systems with polymer erosion/dissolution resulting in a change in
surface area and diameter of particles or tablets.
Q01/3 – Qt1/3 = kHCt……..(4)
Where, Qt is the amount of drug released in time t, Q0 is the initial amount of the drug in the
tablets, and kHC is the rate constant for the Hixson-Crowell rate equation.
Stability studies:
Selected Formulation was subjected to stability studies as per ICH guidelines.
Following conditions were used for Stability Testing.
1. 250C/60% RH analyzed every month for period of three months.
2. 300C/75% RH analyzed every month for period of three months.
3. 400C/75% RH analyzed every month for period of three months.
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FORMULATION DEVELOPMENT 
Procedures: 
The Purpose of key ingredients included in the formulation. 
Table: COMPOSITION OF LAMUVUDINE FLOATING TABLETS
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11
Lamuvudine 100 mg 100 mg 100 mg 100 mg 100 mg 100 mg 100 mg 100 mg 100 mg 100 mg 100 mg
HPMC E 15 50 mg 100 mg 150 mg 200 mg --- --- --- --- 50 mg 100 mg 150 mg
HPMC K 15M --- --- --- --- 50 mg 100 mg 150 mg 200 mg 150 mg 100 mg 50 mg
Sodium bi carbonate 30 mg 30 mg 30 mg 30 mg 30 mg 30 mg 30 mg 30 mg 30 mg 30 mg 30 mg
Citric acid 5 mg 5 mg 5 mg 5 mg 5 mg 5 mg 5 mg 5 mg 5 mg 5 mg 5 mg
Micro Crystalline
Cellulose 255 mg 205 mg 155 mg 105 mg 255 mg 205 mg 155 mg 105 mg 105 mg 105 mg 105 mg
Megnesium stearate 5mg 5mg 5mg 5mg 5mg 5mg 5mg 5mg 5mg 5mg 5mg
Talc 5mg 5mg 5mg 5mg 5mg 5mg 5mg 5mg 5mg 5mg 5mg
Total Weight 450 mg 450 mg 450 mg 450 mg 450 mg 450 mg 450 mg 450 mg 450 mg 450 mg 450 mg
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Preparation of Formulation:
1. Drug and polymers pass through 40 # mesh separately and then transfer the polymer (i.e.
HPMC E15 or HPMC K15M or in combination) into china dish and melt it and then add
the drug and cool to room temperature.
2. Add  diluents  and  other  excipients  to  the  above  mixture.  Finally  add  the  Glidant
(Magnesium Stearate) to the above blend mix it for 2min. 
3. Compressed the above lubricated blend by using 8 mm round punches.
RESULTS AND DISCUSSION
PREFORMULATION:
S.NO API CHARACTERISATION RESULTS
1 Physical Appearance Lamivudine is a white to off-white crystalline solid
2 Melting point 160-162 °C
3 Solubility
Soluble in water; sparingly soluble in methanol,
practically insoluble in acetone.
4 Bulk density 1.16 gm/ml
5 Tapped Density 1.35 gm/ml
6
Carr’s index/Compressibility
index
14.07
7 Hausner’s Ratio 0.99
Conclusion:
The  value  of  compressibility  index  above  25%,  15-25%,  less  than  15%  indicates  poor
flowability, optimum flowability and high flowability respectively. 
List of Micromeritic properties of directly compressible powder:
parameter F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11
Angleof
repose
2705
5’
29o39
’
26074
’
28081’
28065
’
26074
’
28o3
9’
2108
1’
23081’ 26o39’ 20081’
Bulk
density
0.48 0.50 0.66 0.77 0.60 0.55 0.46 0.48 0.66 0.46 0.77
Tapped
density
0.53 0.51 0.76 0.82 0.64 0.58 0.51 0.53 0.76 0.51 0.82
%Compre
ssibility
9.09 3.33 13.15 5.88 5.88 5.00 9.80 9.09 13.15 9.80 5.88
Hausner’s
ratio
1.10 1.03 1.15 1.06 1.06 1.05 1.10 1.10 1.15 1.10 1.06
Lamivudine equivalent  to  100 mg was  weighed and transferred  to  100 ml  volumetric flask,
dissolved in methanol and the final volume was made upto 100 ml with 0.1N HCL. The resulted
solution had the concentration of 1mg/ml (1000µg/ml) which was labeled as “stock solution A”.
 From the stock solution A, 1 ml was pipette out in 10ml volumetric flask and the final
volume was made up to 10ml with 0.1N HCL. The resulted solution had the concentration of
0.1mg/ml (100µg/ml) which was labeled as “stock solution B”. This stock solution B is used as
working stock solution for further study. Further dilutions were prepared from the same solution. 
Preparation of Standard solutions:
              From the stock solution B, further dilution was made with 0.1N HCL in 10 ml
volumetric flasks to get the solutions in the range of 2-10 µg/ml concentration and absorbance
was  recorded  at  280  nm  against  suitable  blank  using  UV-Spectrophotometer  (UV-1601,
Shimadzu, Japan).A calibration curve of absorbance against concentration was plotted and the
drug  follows  the  Beer’s  &  Lambert’s  law  in  the  concentration  range  of  2-10µg/ml.  The
Regression equation and correlation coefficient was determined. 
Table 14: Standard graph of Lamivudine in 0.1 N HCl at λmax= 280nm
S. NO.
CONCENTRATION(µg/ml) ABSORBANCE
1 0
0
2 2 0.130
3 4 0.250
4 6 0.380
5 8 0.510
6 10 0.640
0 2 4 6 8 10 12
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
f(x) = 0.06x - 0
R² = 1
Calibration curve
abs
Linear (abs)
Concentration
A
b
s
o
r
b
a
n
c
e
Evaluation of the Prepared Tablets for Physical Parameters: 
All formulations were tested for Physical parameters like Hardness, thickness, Weight Variation,
Friability  and  found  to  be  within  the  Pharmacopoeial  limits.  The  results  of  the  tests  were
tabulated. The drug content of all the formulations was determined and was found to be within
the permissible limit. This study indicated that all the prepared formulations were good.
Table 15: Results for Evaluation parameters of all formulations
parameter F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11
Weight
variation
450±0.4 449±0.5 449±0.4 450±0.5 449±0.1 450±0.3 450±0.2
450±0.
4
450±0.7 450±0.3 450±0.1
Thickness
(mm) 2.9±0.4 2.8±0.9 2.9±0.2 2.9±0.3 2.8±0.8
2.9±0.2 2.8±0.9 2.5±0.1 2.5±0.2 2.8±0.9 2.5±0.2
Hardness
(kg/cm2)
8.9±1.4 7.4±1.2 8.2±1.2 6.9±0.9 8.4±1.9 8.1±1.7 8.2±1.5 8.3±1.6 8.2±1.4 8.2±1.5 8.3±1.5
Friability
0.22%
±0.2
0.26%
±0.1
0.25%
±0.19
0.25%
±0.3
0.25%
±0.1
0.22%
±0.1
0.21%
±0.4
0.21%
±0.5
0.21%
±0.7
0.21%
±0.4
0.21%
±0.5
The floating tablets of Lamivudine were prepared by using HPMC E15 and HPMC K15M. Nine
different  formulations  were  prepared  using  different  ratios  of  polymers.  The  prepared
formulations  were  evaluated  for  floating  lag  time  and  buoyancy  time.  Sodium  bicarbonate
induced  carbon  dioxide  generation  in  presence  of  dissolution  medium (0.1  N HCl).  It  was
observed that the gas generated is trapped and protected within the matrix, formed by polymers,
thus  density  of  the  tablet  decreased  and  it  becomes  buoyant.  The  floating  lag  time  of  the
optimized formulation F-10 was 30 sec.
In vitro Dissolution studies:
The dissolution conditions used for studying the drug release from tablet of Lamivudine are:
Apparatus : USP apparatus II (Paddle)
Agitation speed (rpm)             : 50rpm
Medium             : 0.1N HCl 
Volume                                     : 900 ml
Temperature             : 37.0 ± 0.5 C
Table 16: Results of Dissolution profile for F1-F11:
Time F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11
0 0 0 0 0 0 0 0 0 0 0 0
1 48.67 43.36 39.67 36.37 33.95 34.67 30.67 33.33 34.95 28.41 37.95
2 66.91 63.92 60.91 58.68 55.78 56.91 53.68 59.76 62.78 49.94 65.78
4 79.67 75.36 71.67 68.37 65.95 68.67 63.67 76.49 73.95 59.45 73.95
6 91.91 89.92 86.91 83.68 79.78 79.91 75.68 87.81 86.78 71.94 84.78
8 99.24 97.92 95.24 93.68 92.94 89.92 86.68 92.67 93.94 83.59 93.94
10 100 100 100 100 97.35 97.32 95.19 96.35 98.28 92.86 99.28
12 100 100 100 99.78 100 99.45 100
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Dissolution  data  of  above  two  methods  was  fitted  in  Zero  order,  First  order  and  Higuchi
equations. The mechanism of drug release was determined by using Higuchi equation.
S.NO time log T
Square
root of
Time
%CR
%Drug
remaining
log %CR
LOG%
DRUG
RETAINED
cube root
of %drug
remaining
0 0 0 0 0 100 0 2 4.641589
1 1 0 1 28.41 71.59 1.453471 1.854852 4.152256
2 2 0.30103 1.414214 49.94 50.06 1.698449 1.699491 3.685505
3 4 0.60206 2 59.45 40.55 1.774152 1.607991 3.435555
4 6 0.778151 2.44949 71.94 28.06 1.85697 1.448088 3.038756
5 8 0.90309 2.828427 83.59 16.41 1.922154 1.215109 2.541184
6 10 1 3.162278 92.86 7.14 1.967829 0.853698 1.9256
7 12 1.079181 3.464102 99.45 0.55 1.997605 -0.25964 0.819321
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Stability Study
There was no significant change in physical and chemical properties of the tablets of formulation
F-10 after 3 Months. Parameters quantified at various time intervals were shown;
 Results of stability studies of optimized formulation F-10
Formulation
Code
Parameters Initial 1st Month 2nd Month 3rd Month
Limits as per
Specifications
F10 25
0C/60%RH
% Release 99.45 99.44 99.38 99.32
Not less than
85 %
F10
300C/75%
RH
% Release
99.45 99.34 99.33 99.31 Not less than85 %
F10
400C/75%
RH
% Release
99.45 99.43 99.38 99.32 Not less than85 %
F10
250C/60%
RH
Assay Value
99.78 99.67 99.64 99.63
Not less than
90 %
Not more than
110 %
F10
300C/75%
RH
Assay Value
99.77 99.66 99.64 99.64
Not less than
90 %
Not more than
110 %
F10
400C/75%
RH
Assay Value
99.77 99.65 99.65 99.64
Not less than
90 %
Not more than
110 %
Stability dissolution profile of F-10 for 1st, 2nd & 3rd months
S.NO. TIME(Hrs) F-10 1M F-10 2M F-10 3M
1 0 0 0 0
2 1 28.41 28.35 27.88
3 2 49.94 49.62 48.91
4 4 59.45 58.40 58.38
5 6 71.94 71.69 70.96
6 8 83.59 83.42 82.83
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Stability dissolution profile of F-10 for 1st, 2nd & 3rd months 
CONCLUSION
The objective of the present study is to develop a Floating matrix tablets of Lamivudine. In this
present  study  an  attempt  was  made  to  increase  the  therapeutic  effect  of  Lamivudine  by
continuously releasing the drug up to an extended period of time by formulating the Floating
matrix tablets. 
Systematic studies were conducted using different concentration of rate releasing polymers like
HPMC E15 and HPMC K15M for extending the drug release up to 12 hrs. All the prepared
systems  were  evaluated  for  the  different  properties.  Before  the  preparation  of  tablets,
preformulation  studies  to  find  out  the  micromeritic  properties  to  assess  flowability,
compressibility properties and solubility studies. And all the formulations gave good results for
above preformulation studies.
Formulated tablets gave satisfactory results for various physical tablet evaluation parameters like
tablet dimensions, hardness, friability, weight variation, content uniformity, all the formulations
were found within the permissible range.
Finally it was concluded that:
Amongall  the formulations  (F1-F11),  it  was  observed  that  Formulation-10  has  shown better
dissolution profile. So Formulation-10 was found to be the best formulation when compared with
other  prepared  formulations.  The  polymers  were  used  at  the  different  concentrations  in  the
formula,  much difference  were  observed in the  release characteristics  of  the  floating tablets
prepared. The release data were analyzed as per zero order, first order, Higuchi and Korsmeyer &
Peppas models.  The correlation coefficient  (r2)  values  in  the analysis  of  release  data as  per
various models are mentioned. Analysis of the release data as per zero order and first order
kinetic models indicated that the drug release from floating tablets formulated followed First
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